ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference
Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of biomarkers in AD
Progress with trial enrollment following DSMB recommendation to proceed to second dose level
CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer's Disease (AD) and its proprietary Discovery Platform, EpiSelectTM, at the Alzheimer's Association International Conference 2025 (AAIC) taking place in Toronto, Canada from July 27-31, 2025.
'We are pleased to share further details of our ongoing Phase 1b PRECISE-AD clinical trial evaluating PMN310, our novel therapeutic candidate for Alzheimer's disease,' said Dr. Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences. 'PRECISE-AD was intentionally designed with a robust framework to assess both the safety and potential signs of efficacy of PMN310. PMN310 is designed to selectively target toxic amyloid-beta oligomers, which are considered a primary driver of Alzheimer's disease, while aiming to reduce the risk of safety issues observed with other therapies. We were encouraged by the recent recommendation from the independent Data and Safety Monitoring Board (DSMB) to proceed to the second dose level, and we have been enrolling patients swiftly into this second cohort.'
'As of this week, more than 50% of the approximately 128 patients planned for the study have been enrolled, reflecting the pace of our clinical progress and the urgent need for new treatment options. To date, we have not observed any cases of amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhages. In addition, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to PMN310, which we believe recognizes the potential of this program to address an unmet medical need in Alzheimer's disease. We anticipate reporting six-month interim data from the study in the second quarter of 2026, with topline results expected by the fourth quarter of 2026,' added Dr. Altstiel.
'The rapid enrollment in PRECISE-AD is a testament to the urgent need to bring new breakthroughs in treatment to Alzheimer's patients and providers,' Dr. David Watson, Chief Executive and Founder of the Alzheimer's Research and Treatment Center and one of the treating physicians in the PRECISE-AD trial stated. 'I am encouraged by the mechanism of ProMIS's PMN310, which has been designed to specifically target toxic Aβ oligomers, and has the potential to provide a more favorable product profile and significantly improve the quality of life of AD patients.'
'Additionally, we are pleased to have been invited to share data supporting the design process and validation of our proprietary target discovery engine, EpiSelectTM, which utilizes advanced computational discovery technologies to identify and target toxic misfolded proteins implicated in neurodegenerative and other misfolded protein diseases,' said Neil Cashman, M.D., Chief Scientific Officer and Co-founder, ProMIS Neurosciences. 'This precision targeting approach has enabled us to design novel therapeutic antibodies with a high degree of selectivity for the key underlying drivers of these conditions.'
Presentation details
Title: Protein misfolding-specific epitope identification for passive and active immunotherapy of neurodegenerative diseases
Presenter: Neil Cashman, M.D., Chief Scientific Officer and Co-founder, ProMIS Neurosciences
Session: Featured Research Session: Advancing Translational Success by Enhancing Predictive Validity in Neurodegenerative Diseases, Thursday, July 31, 2025: 10:00am – 11:30am Eastern Time
Abstract Number: 98670
Title: PRECISE-AD, A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients with Early Alzheimer's Disease
Presenter: Larry Altstiel, M.D., Ph.D., Chief Medical Officer, ProMIS Neurosciences
Session: In Person Poster: Drug Development: Human, Wednesday, July 30, 2025: 7:30am – 4:15pm Eastern Time
Poster Number: 103159
Title: Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease
Joint Presenter: Garret Duncan, Statistician, Pentara Corporation and Johanne Kaplan, Ph.D., Chief Development Officer, ProMIS Neurosciences
Session: In Person Poster: Biomarkers: Biomarkers (non-neuroimaging), Monday, July 28, 2025: 7:30am – 4:15pm Eastern Time
Poster Number: 103841
Abstracts will be available on the
Poster and Publications
page of the Company's website at
www.promis
n
eurosciences.com
following the presentations.
About PMN310 and the PRECISE-AD Clinical Trial
PMN310, the Company's lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to be differentiated in its ability to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing or eliminating ARIA liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics.
Based on the encouraging results from the Phase 1a trial (
NCT06105528
) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (
NCT06750432
) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'pleased to', 'look forward to', 'potential to', 'targets', 'expects' or 'does not expect', 'is expected', 'excited about', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company's progress and expectations for its Phase 1b clinical trial in AD patients, including planned timing for completion and anticipated data readout of interim and full results in the second and fourth quarters of 2026, repsectively, the potential for such studies to provide the first proof-of-concept data for PMN310, the potential for PMN310 to positively benefit patients with AD and to be a more effective and well-tolerated option, the targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of Aβ are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity and the Company's expectations regarding the benefits of Fast Track Designation and management's belief that its proprietary target discovery engine can predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that enrollment may not continue at the current rate, that clinical results or early results may not be indicative of future results, the Company's ability to retain and recognize the incentives conferred by Fast Track Designation for PMN310, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For further information:
Visit us at
www.promisneurosciences.com
Please submit media inquiries to
info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
44 minutes ago
- Hamilton Spectator
Guests of the Shanghai Cooperation Organization Media and Think Tank Summit Visit Luoyang: Embracing the Dynamic Pulse of a Millennia-Old Ancient Capital
LUOYANG, China, Aug. 01, 2025 (GLOBE NEWSWIRE) — From July 23 to 27, the Shanghai Cooperation Organization Media and Think Tank Summit was held in Zhengzhou, Henan Province. On July 26, over 100 guests embarked on a field visit to Luoyang, immersing themselves in the vitality and pulse of this millennium-old ancient capital. A Media Snippet accompanying this announcement is available by clicking on this link. As a pivotal cradle of Chinese civilization, an ancient capital of thirteen dynasties, one of the Eastern starting points of the Silk Road, and a central city along the Grand Canal of Sui and Tang Dynasties, Luoyang boasts over 5,000 years of civilization, nearly 4,000 years of urban history, and more than 1,500 years as a capital. Additionally, it serves as an important traditional industrial base prioritized by the People's Republic of China. During the first Five-Year Plan (1953-1957), seven of 156 key national projects were launched here. In the new era, Luoyang is forging deep integration into the Belt and Road Initiative, as China-Europe and China-Central Asia freight trains operate around the clock. The Silk Road's ancient portal endures, while the radiance of the Tang Dynasty's heyday blooms anew. Dingding Gate stands majestic, having witnessed the distant years when camel bells echoed along the Silk Road and greeted the flourishing glory of the Sui and Tang Dynasties. Stepping into the Site Museum of Dingding Gate, a magnificent reenactment of the 'city entrance ceremony' instantly transported them through history. As performers bowed deeply, their Hanfu robes swirling, the guests marveled at the millennia-old elegance of the cross-handed salute, remarking they had never witnessed such graceful etiquette. Moving to the dazzling 'Wuhuang Shengyan (a Tang-style Cultural Restaurant)', guests embarked on a multisensory journey through the Tang Dynasty's golden age. Amid carved railings and jade-inlaid structures, they savored exquisite delicacies amid resounding music and dance, overwhelmed by the grandeur of Tang majesty. In joyous spirit, guests spontaneously joined performers onstage. Long after the feast, its melodies lingered as the guests remained in awe, exclaiming, 'Stunning! Magnificent! Breathtaking!' They vowed to tell friends and family that they must come and experience it. Dongfanghong composes new stories, while the Buddha's light of Longmen shines upon the world. Entering the Dongfanghong Innovation Hub of YTO Group Corporation, guests felt the surging pulse of Luoyang's equipment manufacturing and industrial development. Interested foreign guests boarded the vehicles to experience the new tractors on display. The accessible advanced manufacturing deeply touched them. 'Luoyang is not only beautiful, but also possesses the crafting might of modern farm machinery, which is truly remarkable!' Many foreign guests noted that China's generous support in professional technologies and equipment had boosted agricultural development in their countries, bolstering the foundations of sustainable growth and safeguarding precious food security. They expressed hope for deeper cooperation ahead. At Longmen Grottoes, guests explored China's treasury of stone carving art. Foreign guests paused before the Giant Vairocana Buddha, remarking that Luoyang is an extraordinarily unique place, rich in culture and civilization. They expressed hope for linking their countries with China through tourism to foster deeper exchanges and mutual learning between civilizations. Millennium-old Luoyang retains its timeless charm. Through this in-depth visit, guests of the Shanghai Cooperation Organization Media and Think Tank Summit not only heard the echoes of history but also felt the city's powerful pulse of the times. They etched deeply in their hearts a 'stunning, magnificent, and breathtaking' magical Luoyang, a city they would share far and wide across the world. Source: The Shanghai Cooperation Organization Media and Think Tank Summit
Hamilton Spectator
6 hours ago
- Hamilton Spectator
Perseus Mining announces retirement of CEO and appointment of new CEO
Perth, Aug. 01, 2025 (GLOBE NEWSWIRE) — perseus mining MANAGING DIRECTOR announces retirement; new MD & CEO appointed SUMMARY Perseus Mining Limited (ASX/TSX:PRU) announces its long-serving Managing Director and Chief Executive Officer (MD and CEO) Jeff Quartermaine has advised he will retire from the role of Perseus's MD and CEO after serving for 12 years. His retirement will take effect from September 30, 2025, after which he has agreed to continue to support the Company through a Consultancy Agreement on market terms. Mr. Quartermaine joined Perseus in 2010 as Chief Financial Officer, before being appointed CEO in 2013. Since assuming this role, he has transformed Perseus from a struggling single-mine, single-country company to a multi-mine, multi-jurisdictional gold producer, developer and explorer that has consistently delivered on its promises and is now one of the leading gold companies operating on the African continent. Perseus now has three operating gold mines, Edikan in Ghana and Yaouré and Sissingué in Côte d'Ivoire, and is building a fourth mine, Nyanzaga, in Tanzania, which is on track to commence gold production in Q1 CY2027. Perseus's Chairman Rick Menell praised Mr Quartermaine's outstanding contribution in leading and shaping Perseus into the company it is today, saying: ' On behalf of the Board, I would like to express my most sincere gratitude to Jeff for his leadership and guidance over the years. Jeff has transformed Perseus and has been pivotal in turning it into one of the most profitable gold producers in the world. He has built extremely solid foundations for the Company to keep growing and we cannot thank him enough for such a positive legacy .' Outgoing MD and CEO, Mr. Quartermaine said: 'It has been an honour and a privilege to have had the opportunity to serve at the helm of Perseus Mining over the past 12 years. Not only has the Company been transformed into a credible ASX 100 organisation, but during this time we have generated significant benefits for all of our stakeholders, including many in our host communities in Africa whose lives have been significantly improved through Perseus's endeavours. I am deeply indebted to all our staff, both past and present, who along with their families have given their friendship, hard work, and commitment in helping transform Perseus. Along the way we have faced a myriad of challenges including events such as the global COVID pandemic, but we have emerged stronger than ever, and the company is now well positioned to continue our success into the future. In reflecting on the last 15 years at Perseus, I must acknowledge the enormous contribution made to my career and indirectly to the success of Perseus, by my own family whose unwavering support has made the journey so much easier.' Mr. Quartermaine will be replaced as MD and CEO by Craig Jones, who will commence work with Perseus on August 18, 2025 and will assume the positions of MD and CEO with effect from October 1, 2025. Mr Jones joins Perseus with more than 25 years of global experience, having worked across Australia, Papua New Guinea (PNG), Indonesia and Canada. He was a member of Newcrest's executive team from 2012, having originally joined in 2008, and ultimately serving as Newcrest's global COO, with broad responsibility for five operating assets spread across multiple jurisdictions. In that capacity, he played a critical role in the development of organisational strategies, due diligence and investor relations. Mr Jones also led high-level engagement with governments, communities and First Nations groups across PNG, Canada and Australia. Beyond his executive roles, Mr. Jones was a Newcrest nominee director on the Boards of SolGold and Lundin Gold and was Newcrest's representative on Joint Venture Committees including the Morobe Mining Joint Venture in PNG and the Red Chris Joint Venture in British Columbia, reflecting extensive global resource-sector connectivity and governance experience. A values-driven leader recognised for enhancing safety and fostering a strong organisational culture, Mr Jones is known for his consistent, empathetic and principled leadership style, which has earned the respect of peers, governments and communities alike. Mr Menell said: 'We are delighted to welcome Craig to the Perseus team as Managing Director and CEO. Perseus is going through a significant phase of growth, in an environment that is getting increasingly complex, so we need a leader of Craig's calibre to build on Jeff's incredible legacy and confirm – and further grow – our position as one of the world's better performing mid-tier gold producers. Craig brings a wealth of strategic, operational and technical expertise, a deep understanding of complex operating jurisdictions and stakeholder management and a clear commitment to sustainable practices. We look forward to working with Craig and the rest of the Perseus team to bring the Company even further.' Mr. Jones will be based in Perseus's head office in Perth, Western Australia. A summary of the material terms of the employment agreement between Perseus and Mr. Jones is provided in Appendix A of this announcement. Appendix A: CEO Summary of Key Terms of employment This market announcement was authorised for release by the Chairman of the Board of Perseus Mining Limited, Rick Menell.
Hamilton Spectator
6 hours ago
- Hamilton Spectator
Acceleware Ltd. Announces Closing of First Tranche of Non-Brokered Private Placement
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. ('Acceleware' or the 'Company') (TSX-V: AXE), a leading innovator of cutting-edge radio frequency ('RF') power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, announces that the Company closed the first tranche of the non-brokered private placement of units (the 'Units') that it previously announced on June 30, 2025 (the 'Private Placement') and distributed a total of 7,913,342 Units, at a price of $0.10 per Unit, for total gross proceeds of $791,334.20. It is anticipated that one or more subsequent tranches of the Private Placement will be closed in due course. Each Unit consists of one common share of the Company (a 'Common Share') and one common share purchase warrant of the Company (a 'Warrant'). Each Warrant entitles the holder of the Warrant to acquire one Common Share, at an exercise price of $0.20, which will expire which will expire 24 months from the date of issuance. If the Common Shares trade at a closing price at or greater than $0.30 per Common Share for a period of thirty (30) consecutive trading days, Acceleware may accelerate the expiry date of the Warrants by giving notice to the holders thereof, and in such case, the Warrants will expire on the 30th day after the date on which such notice is given by Acceleware. The Common Shares issued in connection with the Private Placement, the Warrants, and any Common Shares issued upon exercise of the Warrants will be subject to a four-month hold period which will expire on December 2, 2025 in accordance with applicable securities legislation. There were no finders' fees or commissions paid in connection with the Private Placement. The Company expects to use the proceeds of the Private Placement to fund a portion of the Company's RF XL 2.0 redeployment plan, to advance commercialization of new RF heating applications, including critical minerals applications and amine regeneration applications including carbon capture, and for general corporate purposes. Insiders of the Company purchased a total of 1,300,000 Units under the Private Placement, which is considered a related party transaction within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ('MI 61-101'). Acceleware relied on the exemptions from the formal valuation and minority approval requirements of MI 61-101 based on a determination that the fair market value of the Private Placement does not exceed 25% of the market capitalization of the Company. No new insiders and no control persons were created in connection with the Private Placement. About Acceleware Acceleware is an advanced electromagnetic heating company with cutting-edge RF power-to-heat solutions for large industrial applications. The Company's technologies provide an opportunity to electrify and decarbonize industrial process heat applications while reducing costs. The Company is working to use its patented and field proven Clean Tech Inverter to materially improve the efficiency of amine regeneration, and has partnered with a consortium of world-class potash partners seeking to decarbonize drying of potash ore and other critical minerals. Acceleware is actively developing other process heat applications and partnerships for RF heating. Acceleware's RF XL is a patented low-cost, low-carbon RF thermal enhanced oil production technology for heavy oil that is materially different from any enhanced recovery technique used today. Acceleware is a public company listed on the TSXV under the trading symbol 'AXE'. Cautionary Statements This news release contains forward-looking statements and/or forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable securities laws. When used in this release, such words as 'will', 'anticipates', 'believes', 'intends', 'expects' and similar expressions, as they relate to Acceleware, or its management, are intended to identify such forward-looking statements. Such forward-looking statements reflect the current views of Acceleware with respect to future events, and are subject to certain risks, uncertainties and assumptions. Many factors could cause Acceleware's actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements. Certain information and statements contained in this news release constitute forward-looking statements, which reflects Acceleware's current expectations regarding future events, including, but not limited to the use of proceeds under the Private Placement; the anticipated completion of any additional tranches of the Private Placement; the receipt of applicable approvals and exemptions (including the Company's board of directors, shareholders, and regulatory approvals including approval of the TSXV) relating to any additional tranches of the Private Placement, the statutory hold periods applicable to the Units and; the anticipated participation by insiders in the Private Placement. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the availability of investment capital and other funding; receipt of necessary approvals; availability of financing for technology and project development; uncertainties and risks with respect to developing and adopting new technologies; general business, economic, competitive, political and social uncertainties; change in demand for technologies to be offered by the Company; obtaining required approvals of regulatory authorities and/or shareholders, as applicable; ability to access sufficient capital from internal and external sources. For a more fulsome list of risk factors please see the Company's December 31, 2024, year-end Management Discussion and Analysis ('MD&A') available on SEDAR+ at . Management of the Company has included the above summary of assumptions and risks related to forward-looking statements provided in this release to provide shareholders with a more complete perspective on the Company's current and future operations and such information may not be appropriate for other purposes. The Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act') or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. For more information: Geoff Clark Tel: +1 (403) 249-9099
